FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245125364> ?p ?o ?g. }

• W4245125364 abstract "Abstract Background: Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate turbulence (HRT). The EMBODY trial was designed to determine whether the Sodium–glucose cotransporter 2 (SGLT2) inhibitor improves cardiac nerve activity. Methods: This prospective, multicenter, randomized, double-blind, placebo-controlled trial included patients with AMI and T2DM in Japan; 105 patients were randomized (1:1) to receive once-daily 10-mg empagliflozin or placebo. The primary endpoints were changes in HRV, e.g., the standard deviation of all 5-min mean normal RR intervals (SDANN) and the low-frequency–to–high-frequency (LF/HF) ratio from baseline to 24 weeks. Secondary endpoints were changes in other sudden cardiac death (SCD) surrogate markers such as HRT. Results: Overall, 96 patients were included (46, empagliflozin group; 50, placebo group). The changes in SDANN were +11.6 and +9.1 msec in the empagliflozin (P=0.02) and placebo groups (P=0.06), respectively. Change in LF/HF ratio was –0.57 and –0.17 in the empagliflozin (P=0.01) and placebo groups (P=0.43), respectively. Significant improvement was noted in HRT only in the empagliflozin group (P=0.01). Whereas intergroup comparison on HRV and HRT showed no significant difference between the empagliflozin and placebo groups. Compared with the placebo group, the empagliflozin group showed significant decreases in body weight, systolic blood pressure, and uric acid. In the empagliflozin group, no adverse events were observed. Conclusions: This is the first randomized clinical data to evaluate the effect of empagliflozin on cardiac sympathetic and parasympathetic activity in patients with T2D and AMI. Early SGLT2 inhibitor administration in AMI patients with diabetes mellitus might be effective in improving cardiac nerve activity without any adverse events. Trial Registration: The EMBODY trial was registered by the UMIN in November 2017 (ID: 000030158). UMIN000030158; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034442" @default.
• W4245125364 created "2022-05-12" @default.
• W4245125364 creator A5000083090 @default.
• W4245125364 creator A5010491253 @default.
• W4245125364 creator A5011698980 @default.
• W4245125364 creator A5014897518 @default.
• W4245125364 creator A5018636917 @default.
• W4245125364 creator A5019563599 @default.
• W4245125364 creator A5026424147 @default.
• W4245125364 creator A5031308958 @default.
• W4245125364 creator A5031912207 @default.
• W4245125364 creator A5047525722 @default.
• W4245125364 creator A5051062977 @default.
• W4245125364 creator A5051639102 @default.
• W4245125364 creator A5055198458 @default.
• W4245125364 creator A5057896442 @default.
• W4245125364 creator A5058527965 @default.
• W4245125364 creator A5070179989 @default.
• W4245125364 creator A5070991795 @default.
• W4245125364 creator A5077875550 @default.
• W4245125364 creator A5085343317 @default.
• W4245125364 date "2020-06-25" @default.
• W4245125364 modified "2023-09-28" @default.
• W4245125364 title "Effects of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: The EMBODY Trial" @default.
• W4245125364 doi "https://doi.org/10.21203/rs.3.rs-35207/v1" @default.
• W4245125364 hasPublicationYear "2020" @default.
• W4245125364 type Work @default.
• W4245125364 citedByCount "0" @default.
• W4245125364 crossrefType "posted-content" @default.
• W4245125364 hasAuthorship W4245125364A5000083090 @default.
• W4245125364 hasAuthorship W4245125364A5010491253 @default.
• W4245125364 hasAuthorship W4245125364A5011698980 @default.
• W4245125364 hasAuthorship W4245125364A5014897518 @default.
• W4245125364 hasAuthorship W4245125364A5018636917 @default.
• W4245125364 hasAuthorship W4245125364A5019563599 @default.
• W4245125364 hasAuthorship W4245125364A5026424147 @default.
• W4245125364 hasAuthorship W4245125364A5031308958 @default.
• W4245125364 hasAuthorship W4245125364A5031912207 @default.
• W4245125364 hasAuthorship W4245125364A5047525722 @default.
• W4245125364 hasAuthorship W4245125364A5051062977 @default.
• W4245125364 hasAuthorship W4245125364A5051639102 @default.
• W4245125364 hasAuthorship W4245125364A5055198458 @default.
• W4245125364 hasAuthorship W4245125364A5057896442 @default.
• W4245125364 hasAuthorship W4245125364A5058527965 @default.
• W4245125364 hasAuthorship W4245125364A5070179989 @default.
• W4245125364 hasAuthorship W4245125364A5070991795 @default.
• W4245125364 hasAuthorship W4245125364A5077875550 @default.
• W4245125364 hasAuthorship W4245125364A5085343317 @default.
• W4245125364 hasBestOaLocation W42451253641 @default.
• W4245125364 hasConcept C126322002 @default.
• W4245125364 hasConcept C134018914 @default.
• W4245125364 hasConcept C142724271 @default.
• W4245125364 hasConcept C164705383 @default.
• W4245125364 hasConcept C204787440 @default.
• W4245125364 hasConcept C27081682 @default.
• W4245125364 hasConcept C2775887513 @default.
• W4245125364 hasConcept C2777953023 @default.
• W4245125364 hasConcept C2910068830 @default.
• W4245125364 hasConcept C42219234 @default.
• W4245125364 hasConcept C500558357 @default.
• W4245125364 hasConcept C555293320 @default.
• W4245125364 hasConcept C71635504 @default.
• W4245125364 hasConcept C71924100 @default.
• W4245125364 hasConcept C84393581 @default.
• W4245125364 hasConceptScore W4245125364C126322002 @default.
• W4245125364 hasConceptScore W4245125364C134018914 @default.
• W4245125364 hasConceptScore W4245125364C142724271 @default.
• W4245125364 hasConceptScore W4245125364C164705383 @default.
• W4245125364 hasConceptScore W4245125364C204787440 @default.
• W4245125364 hasConceptScore W4245125364C27081682 @default.
• W4245125364 hasConceptScore W4245125364C2775887513 @default.
• W4245125364 hasConceptScore W4245125364C2777953023 @default.
• W4245125364 hasConceptScore W4245125364C2910068830 @default.
• W4245125364 hasConceptScore W4245125364C42219234 @default.
• W4245125364 hasConceptScore W4245125364C500558357 @default.
• W4245125364 hasConceptScore W4245125364C555293320 @default.
• W4245125364 hasConceptScore W4245125364C71635504 @default.
• W4245125364 hasConceptScore W4245125364C71924100 @default.
• W4245125364 hasConceptScore W4245125364C84393581 @default.
• W4245125364 hasLocation W42451253641 @default.
• W4245125364 hasLocation W42451253642 @default.
• W4245125364 hasLocation W42451253643 @default.
• W4245125364 hasOpenAccess W4245125364 @default.
• W4245125364 hasPrimaryLocation W42451253641 @default.
• W4245125364 hasRelatedWork W11138576 @default.
• W4245125364 hasRelatedWork W16158435 @default.
• W4245125364 hasRelatedWork W17115363 @default.
• W4245125364 hasRelatedWork W18717468 @default.
• W4245125364 hasRelatedWork W18749133 @default.
• W4245125364 hasRelatedWork W19079713 @default.
• W4245125364 hasRelatedWork W19526496 @default.
• W4245125364 hasRelatedWork W21478844 @default.
• W4245125364 hasRelatedWork W2242183 @default.
• W4245125364 hasRelatedWork W6699458 @default.
• W4245125364 isParatext "false" @default.
• W4245125364 isRetracted "false" @default.
• W4245125364 workType "article" @default.